AstraZeneca Pharma India Limited (BOM:506820)
8,567.20
-150.85 (-1.73%)
At close: Apr 15, 2026
AstraZeneca Pharma India Revenue
AstraZeneca Pharma India had revenue of 6.12B INR in the quarter ending December 31, 2025, with 38.90% growth. This brings the company's revenue in the last twelve months to 21.77B, up 34.49% year-over-year. In the fiscal year ending March 31, 2025, AstraZeneca Pharma India had annual revenue of 17.16B with 32.48% growth.
Revenue (ttm)
21.77B
Revenue Growth
+34.49%
P/S Ratio
9.79
Revenue / Employee
36.29M
Employees
600
Market Cap
213.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 17.16B | 4.21B | 32.48% |
| Mar 31, 2024 | 12.96B | 2.93B | 29.17% |
| Mar 31, 2023 | 10.03B | 1.97B | 24.50% |
| Mar 31, 2022 | 8.06B | -79.60M | -0.98% |
| Mar 31, 2021 | 8.14B | -182.50M | -2.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 79.18B |
| Abbott India | 68.24B |
| Granules India | 50.92B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| GlaxoSmithKline Pharmaceuticals | 38.01B |
| Caplin Point Laboratories | 20.92B |
| Sanofi India | 18.37B |
| Viyash Scientific | 18.17B |
AstraZeneca Pharma India News
- 6 days ago - AstraZeneca Pharma India secures approval to market Calquence for new indication - Business Upturn
- 8 days ago - AstraZeneca, Telangana govt to roll out AI-powered lung cancer screening in public hospitals - The Times of India
- 16 days ago - AstraZeneca Pharma India appoints Dr. Shashank Srinivasan and promotes Mr. Venkat Natarajan - Business Upturn
- 27 days ago - AstraZeneca Pharma India announces resignation of non-executive director Jesús Diaz-Ropero Esteso - Business Upturn
- 4 weeks ago - AstraZeneca Pharma India receives approval to market Imfinzi for unresectable hepatocellular carcinoma - Business Upturn
- 2 months ago - ASTRAZEN shares fall over 4% as Q3 EBITDA drops 41.8% YoY to Rs 44.8 crore - Business Upturn
- 2 months ago - Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment - NDTV
- 4 months ago - AstraZeneca Pharma India receives CDSCO approval to import and market Datverzo in India - Business Upturn